ZURAGARD
Peakisopropyl alcohol
NDATOPICALSOLUTION
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
ZURAGARD (isopropyl alcohol) is 2 (d 2 ) and serotonin type 2 (5ht 2 ) antagonism. First approved in 2019.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZURAGARD is a topical isopropyl alcohol solution approved in April 2019 for dermatological use. Despite the mechanistic data indicating dopamine D2 and serotonin 5HT2 antagonism, the topical route and alcohol formulation suggest a local antiseptic or skin preparation indication. The product is currently in peak commercial lifecycle phase.
Peak9.6 years to LOE
Product is at peak lifecycle with minimal competitive pressure (score: 0), suggesting stable but non-expanding market opportunity for commercial teams.
Mechanism of Action
2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZURAGARD career opportunities are concentrated in manufacturing and operations, with only 2 linked roles reflecting a stable, mature product with limited commercial team headcount. This is a manufacturing-intensive asset suitable for supply chain, quality, and technical operations professionals rather than commercial or medical affairs generalists.
Clean & Packaging Technician 1Line Lead
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.